BackTaysha Gene Therapies Overview

Taysha Gene Therapies Other Liabilities

Latest other liabilities for TSHA: $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Taysha Gene Therapies Other Liabilities History

Loading

Taysha Gene Therapies vs. peers: Other Liabilities Comparison

Loading

Taysha Gene Therapies Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Taysha Gene Therapies (TSHA) FAQ

As of the most recent data (June 2026), TSHA shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TSHA's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Taysha Gene Therapies is outperforming or lagging.

Tracking TSHA's other liabilities over time shows whether Taysha Gene Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Taysha Gene Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

Taysha Gene Therapies's other liabilities is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.